Therapeutic Targeting of the GSK3β-CUGBP1 Pathway in Myotonic Dystrophy is a research paper published in International Journal of Molecular Sciences (2023). On theSindex it has a DataRank of 0.373. It has been cited 11 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.373
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →NIH
Grant: 5RO1NS115662
NIH
Grant: 5RO1AR073379
NINDS NIH HHS
Grant: R01 NS115662
NIAMS NIH HHS
Grant: R01 AR073379
National Institutes of Health
Grant: 5R01AR073379-03
GSK3 beta study in patients with Myotonic Dystrophy 1
National Institutes of Health
Grant: 5R01NS115662-03
CNS in Congenital DM1: Pathogenesis and Therapeutic Opportunities
MeSH Terms
Keywords